%0 Journal Article
%T Val66Met Polymorphism in BDNF Has No Sexual and APOE ¦Å4 Status
%A Lining Si
%A Qingnan Zhao
%A Shan Jiang
%A Yanli Zhao
%A Yaqi Shen
%A Yu Qiu
%A null
%J American Journal of Alzheimer's Disease & Other Dementias£¿
%@ 1938-2731
%D 2018
%R 10.1177/1533317517733037
%X Some studies showed that Val66Met polymorphism of brain-derived neurotrophic factor (BDNF) conveys susceptibility to Alzheimer¡¯s disease (AD) in females only. However, the confounding effects of some risk factors for AD were omitted in these studies. The aim of this meta-analysis comprising 19 604 patients with AD and 26 333 controls was to reexamine the association between Val66Met and AD by conditioning the effects of age, sex, and/or apolipoprotein E (APOE) ¦Å4 status. In agreement with the previous meta-analysis, Val66Met was associated with AD in females without confounding adjustment (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.03-1.14; P = .003). Nevertheless, after adjusting for age and APOE ¦Å4 status, Val66Met was not associated with AD in females (OR, 1.02; 95% CI, 0.94-1.11; P = .57). This comprehensive meta-analysis with the largest sample size demonstrated no association could be observed between Val66Met and AD in general or by dividing samples based on sex or APOE ¦Å4
%K Alzheimer¡¯s disease
%K brain-derived neurotrophic factor
%K Val66Met polymorphism
%K meta-analysis
%K high-throughput genotyping
%U https://journals.sagepub.com/doi/full/10.1177/1533317517733037